A Phase I study of CER-209 in healthy volunteers for the clinical investigation of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato-Hepatitis (NASH).
Phase of Trial: Phase I
Latest Information Update: 22 Dec 2016
At a glance
- Drugs CER 209 (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Adverse reactions
- 22 Dec 2016 New trial record
- 15 Dec 2016 According to Cerenis Therapeutics media release, company plans to begin enrollment in Q1 2017.